Creso Pharma (CPH) Stock Price, News & Analysis

Company Overview

Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $23.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CPH Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Creso Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Creso Pharma investors own include Evolution Mining (EVN), Skin Elements (SKN), Santos (STO), Aurizon (AZJ), C29 Metals (C29), CIMIC Group (CIM) and CSL (CSL).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: ASX:CPH
• CIK: N/A
• Web: www.cresopharma.com
• Phone: 61 2 8067 8606
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.78 million
• Net Margins: -377.28%
• Pretax Margin: N/A
• Return on Equity: -130.99%
• Return on Assets: -35.93%

Debt

• Debt-to-Equity Ratio: 29.92
• Current Ratio: 0.76
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $8.92 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,570,000,000
• Free Float: N/A
• Market Cap: $23.11 million
• Optionable: Not Optionable
• Beta: 2.62